BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 15084661)

  • 1. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
    Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
    J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid Rafts Act as a Common Platform for Amyloid-β Oligomer-Induced Alzheimer's Disease Pathology.
    Kawarabayashi T; Nakamura T; Sato K; Seino Y; Ichii S; Nakahata N; Takatama M; Westaway D; George-Hyslop PS; Shoji M
    J Alzheimers Dis; 2022; 87(3):1189-1203. PubMed ID: 35431249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG
    J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts.
    Hernandez P; Lee G; Sjoberg M; Maccioni RB
    J Alzheimers Dis; 2009; 16(1):149-56. PubMed ID: 19158430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
    Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM
    J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.
    Fernandez-Echevarria C; Díaz M; Ferrer I; Canerina-Amaro A; Marin R
    Neuroscience; 2014 Oct; 278():354-66. PubMed ID: 25168729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism.
    Williamson R; Usardi A; Hanger DP; Anderton BH
    FASEB J; 2008 May; 22(5):1552-9. PubMed ID: 18096814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.
    Sadowski MJ; Pankiewicz J; Scholtzova H; Mehta PD; Prelli F; Quartermain D; Wisniewski T
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18787-92. PubMed ID: 17116874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomerization of amyloid beta-protein occurs during the isolation of lipid rafts.
    Yu W; Zou K; Gong JS; Ko M; Yanagisawa K; Michikawa M
    J Neurosci Res; 2005 Apr; 80(1):114-9. PubMed ID: 15704187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
    Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
    Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
    Tackenberg C; Kulic L; Nitsch RM
    PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition.
    Sawmiller D; Habib A; Hou H; Mori T; Fan A; Tian J; Zeng J; Giunta B; Sanberg PR; Mattson MP; Tan J
    Biol Psychiatry; 2019 Aug; 86(3):208-220. PubMed ID: 31208706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
    Sadowski M; Pankiewicz J; Scholtzova H; Ripellino JA; Li Y; Schmidt SD; Mathews PM; Fryer JD; Holtzman DM; Sigurdsson EM; Wisniewski T
    Am J Pathol; 2004 Sep; 165(3):937-48. PubMed ID: 15331417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of intraneuronal β-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses.
    Takahashi RH; Capetillo-Zarate E; Lin MT; Milner TA; Gouras GK
    PLoS One; 2013; 8(1):e51965. PubMed ID: 23372648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
    Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
    Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.